ClinicalTrials.gg
RecruitingNCT06788587Updated Feb 23, 2026

Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder

A Phase 2 interventional study of LDX-01 plus TAU and Placebo plus TAU in Methamphetamine Abuse, Methamphetamine-dependence and Addiction, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Primary conditionSubstance-Related DisordersRegistry: Behavior, AddictiveReclassifiedWhy we changed it
Registry
Behavior, Addictive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Substance-Related Disorders
Why
  1. Behavior, Addictive is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Substance-Related Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.

Planned enrollment
33rd of 71
80 · median 74
Started
2025
with 5 others
Phase 2
5 of 81
2 open now
Primary completion
2027-08
later than 19 of 28 live
Registered
72nd of 81
by date
Lead sponsor
3 of 81
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is the 33rd largest by planned enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 19 of the 28 other live ones, and was the 72nd registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Substance-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.

The goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.

Participants will be placed randomly into one of two groups:

  1. TAU and high-dose LDX-01
  2. TAU and placebo
Read the detailed description

This trial is a single-centre, randomized double-blind (LDX-01), dose-ascending, placebo-controlled trial. This study is an extension to a parent trial, Addition of high-dose stimulant and engagement-focused contingency management, alone and in combination, to treatment as usual for the management of methamphetamine use disorder (ASCME): a pan-Canadian multi-centre, randomized, controlled trial (NCT05854667). Participants will be enrolled in one of the 2 treatment arms:

Arm 1 : TAU plus high-dose LDX-01 Arm 2 : TAU plus placebo

The trial will enroll 62-80 participants who have completed the parent trial in the Quebec site. The participants will be enrolled in the trial for 30 weeks.

Participation includes the following:

  1. Participants will receive medication or placebo weekly for 25 weeks
  2. Participants will attend the clinic for weekly treatment
  3. Participants will attend the clinic once every week for study visits. At these visits, participants will be asked to provide a urine sample (Weeks 1-25: every two weeks, week 26 and week 30) and/or complete questionnaires
03

Conditions studied

  • Methamphetamine Abuse
  • Methamphetamine-dependence
  • Addiction
  • Substance Abuse
  • Methamphetamine Use Disorder

Browse trials for

Keywords

  • Substance use disorder
  • Amphetamines
  • Methamphetamine
  • Lisdexamfetamine
  • Treatment
  • Agonist therapy
  • Feasibility
04

In context

Substance-Related Disorders Reclassified

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

This study's planned enrollment of 80 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.

Compared within Substance-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Behavior, Addictive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 55 years of age at enrollment in the parent ASCME trial;
  2. Diagnosed with a moderate to severe MUD as defined by the criteria;
  3. Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1;
  4. Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use;
  5. Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD;
  6. If female:

    • Be of non-, defined as (i) (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or
    • Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of throughout the study;
  7. Willing to be randomized to one of 2 study arms and followed for the duration of the trial;
  8. Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002);
  9. Able to provide ;
  10. Willing to comply with study procedures;
  11. Able to communicate in English or French

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully ;
  2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study;
  3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for \<12 weeks, and not yet at stabilization dose, or at stabilization dose \<4 weeks;
  4. Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study;
  5. History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines;
  6. Pregnant, nursing, or planning to become pregnant during the study period;
  7. Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study;
  8. Use of an drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial;
  9. Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening;
  10. Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors [MAOIs]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician;
  11. measurement (Bazett method for the correction of ) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening;
  12. Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study;
  13. Any compliance issues related to the study product and/or study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    LDX-01 + TAU

    Participants will receive TAU at the clinic as well as once daily over-encapsulated LDX-01 orally for 25 weeks.

    Drug: LDX-01 plus TAU

  • Placebo comparator
    Placebo + TAU

    Participants will receive TAU at the clinic as well as once daily LDX-01-matched placebo orally for 25 weeks.

    Drug: Placebo plus TAU

Interventions

  • DrugLDX-01 plus TAU

    Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).

  • DrugPlacebo plus TAU

    Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).

07

What researchers measure

Primary outcomes

  1. Retention in treatment

    Retention in treatment will be measured as the proportion of study participants who receive any intervention during the 4 weeks before week 22 and 4 weeks before week 26

    Time frame: Weeks 18, 19, 20, 21 and weeks 22, 23, 24, 25

  2. Treatment satisfaction

    Participant treatment satisfaction will be measured by evaluating participant satisfaction using the Client Satisfaction Questionnaire-8 (CSQ-8) questionnaire. The total score ranges from 8 (minimum) to 32 (maximum) with the higher values showing greater satisfaction.

    Time frame: Weeks 22, 26

  3. Retention in study

    Retention in study will be measured as 1) the proportion of study participants who return for the study visit at week 22 with or without receiving the study interventions, 2) the proportion of study participants who return for the study visit at week 26 with or without receiving the study interventions, and 3) the proportion of study participants who return for the last study visit at week 30 with or without receiving the study interventions.

    Time frame: Weeks 22, 26 and 30

  4. Treatment adherence

    Treatment adherence will be first, measured individually, as the total proportion of the number of the assigned medications (LDX-01/placebo) taken through the intervention (from baseline until the end of week 25) and then averaged across all study completers.

    Time frame: from week 1 day 1 to week 25

Other outcomes

  1. Safety events

    Safety of long-term high-dose LDX-01 will be assessed through the collection of adverse event (AEs) and serious adverse event (SAEs). The number and proportions of each AE, SAE, adverse drug reaction (ADR), and unexpected ADR will be recorded weekly. For calculations, each participant's safety-related event will be counted once under the maximum severity or the strongest recorded causal relationship to study medication

    Time frame: up to 30 weeks : from the date of enrollment until week 30

  2. QTc measurement

    QTc will be measured using ECG; incidence of borderline prolonged (460-479 milliseconds for females and 450-469 milliseconds for males) and prolonged ( ≥ 480 milliseconds for females and ≥ 470 milliseconds for males) QTc interval will be measured using the Bazett method for the correction of QT interval.

    Time frame: Screening, weeks 1, 2, 3, 7 and 22

  3. Self-reported methamphetamine use

    Self-reported methamphetamine use, is measured using the self-reported number of days of methamphetamine use during the 29 weeks of the study using the Timeline Follow Back (TLFB) Questionnaire since the last study visit, or in the past 28 days, whichever number of days is the least (i.e., researcher-administered, with memory cues to improve accuracy).

    Time frame: Baseline, week 1 day 1, weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 26 and 30

  4. Methamphetamine use by urinalysis

    Methamphetamine use by urinalysis will be measured by the number of reactive urine samples tested for methamphetamine using the rapid chromatographic immunoassays for urine drug screen (UDS). All urine specimens will be collected and analyzed using a Rapid Response Multi- Drug One Step Screen Test Panel, following the manufacturer's recommended procedures to test for the presence of the following drugs or their respective metabolites: methamphetamine, morphine, fentanyl, benzodiazepines, cocaine, THC, methadone, buprenorphine, methylphenidate, MDMA, LSD, ketamine, oxycodone, heroin, Hydromorphone and amphetamine (week 30 only). A validity check will be performed using an adulterant strip included in the test.

    Time frame: week 1 day 1, weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 26 and 30

  5. Amphetamine craving

    Amphetamine craving will be measured using the Brief Substance Craving Scale (BSCS). The BSCS is a 16-item, self-report instrument which assesses cravings for substances over 24-hour period. It has good psychometric properties. Intensity, frequency, and length of cravings are recorded on a five-point Likert scale. the total score is 0 (minimum) to 12 (maximum) with higher values indicating a larger craving.

    Time frame: week 1 day 1, weeks 12, 22, 26 and 30

  6. Addiction severity

    Addiction severity is measured with the Addiction Severity Index (ASI), a Self-Report questionnaire that captures substance abuse participants' functioning. It has good psychometric properties, with good consistency and test-retest reliabilities. The ASI Self-Report assesses problem use in the past 30 days in seven areas commonly affected by substance use, including medical, employment/support, alcohol, drug, legal, family/social, and psychiatric drug sections.

    Time frame: week 1 day 1, weeks 12, 22, 26 and 30

  7. Changes in Quality of life

    Quality of life will be measured using the World Health Organization Quality of Life - BREF (WHOQOL-BREF), a person-centred generic patient-reported quality of life measure, validated to document and follow changes in quality of life in different physical and psychiatric disorders. It specifically looks at 4 domains related to quality of life: physical health, psychological health, social relationships, and environment. Domain scores for the WHOQOL-BREF are calculated by taking the mean of all items included in each domain and multiplying by a factor of four. These scores are then transformed to a 0-100 scale with the higher values showing greater quality of life.

    Time frame: week 1 day 1, weeks 12, 22, 26 and 30

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Of 47 non-industry phase 2 interventional studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 51. This study's planned 25 months is below that.

Counting every sponsor, half of 51 studies reached it within 35 months; a quarter within 24 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 23, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06788587
Collaborators
Ministere de la Sante et des Services Sociaux, Health Canada
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Jul 18, 2025
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 23, 2026

Study contacts

Devon Blanchette
Contact
dblanchette@changemark.ca
780-953-6630
Amina Sow, Ph.D
Contact
amina.sow.chum@ssss.gouv.qc.ca
438-860-2452
Didier Jutras-Aswad, MD
principal investigator · CHUM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion